Martin Armstrong

3.3k total citations · 1 hit paper
31 papers, 1.9k citations indexed

About

Martin Armstrong is a scholar working on Molecular Biology, Pharmacology and Cardiology and Cardiovascular Medicine. According to data from OpenAlex, Martin Armstrong has authored 31 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Molecular Biology, 11 papers in Pharmacology and 8 papers in Cardiology and Cardiovascular Medicine. Recurrent topics in Martin Armstrong's work include Pharmacogenetics and Drug Metabolism (10 papers), Drug Transport and Resistance Mechanisms (4 papers) and Antiplatelet Therapy and Cardiovascular Diseases (4 papers). Martin Armstrong is often cited by papers focused on Pharmacogenetics and Drug Metabolism (10 papers), Drug Transport and Resistance Mechanisms (4 papers) and Antiplatelet Therapy and Cardiovascular Diseases (4 papers). Martin Armstrong collaborates with scholars based in United Kingdom, Belgium and United States. Martin Armstrong's co-authors include Robert F. Storey, Ann K. Daly, Steen Husted, Jeffrey R. Idle, Jay Horrow, Svati H. Shah, Richard C. Becker, Lars Wallentin, Bryan J. Barratt and Philippe Gabríel Steg and has published in prestigious journals such as The Lancet, Circulation and Nature Communications.

In The Last Decade

Martin Armstrong

29 papers receiving 1.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial

2010 582 citations Lars Wallentin, Stefan James et al. The Lancet profile →

Peers

Martin Armstrong

CCM

PHARM

SURGE

ONCOL

Jean Combalbert France

C. Steven Ernest United States

Antonio González‐Pérez Spain

Giovanna D’Andrea Italy

Lina Quteineh Switzerland

Min‐Ji Charng Taiwan

Francesca Catella-Lawson United States

Michael Pacanowski United States

Joshua P. Lewis United States

Joseph R. Walker United States

Jean Combalbert France

Martin Armstrong

778 ×0.8

CCM

579 ×1.0

PHARM

201 ×0.5

309 ×0.8

SURGE

316 ×1.1

ONCOL

Citations per year, relative to Martin Armstrong Martin Armstrong (= 1×) peers Jean Combalbert

Countries citing papers authored by Martin Armstrong

Since Specialization

Citations

This map shows the geographic impact of Martin Armstrong's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Martin Armstrong with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Martin Armstrong more than expected).

Fields of papers citing papers by Martin Armstrong

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Martin Armstrong. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Martin Armstrong. The network helps show where Martin Armstrong may publish in the future.

Co-authorship network of co-authors of Martin Armstrong

This figure shows the co-authorship network connecting the top 25 collaborators of Martin Armstrong. A scholar is included among the top collaborators of Martin Armstrong based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Martin Armstrong. Martin Armstrong is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Aschenbrenner, Dominik, Isar Nassiri, Suresh Venkateswaran, et al.. (2024). An isoform quantitative trait locus in SBNO2 links genetic susceptibility to Crohn’s disease with defective antimicrobial activity. Nature Communications. 15(1). 4529–4529.

Birkenbihl, Colin, Ashar Ahmad, Tamara Raschka, et al.. (2023). Artificial intelligence-based clustering and characterization of Parkinson's disease trajectories. Scientific Reports. 13(1). 2897–2897. 10 indexed citations

Bienfait, Karina, Aparna Chhibber, Jean‐Claude Marshall, et al.. (2021). Current challenges and opportunities for pharmacogenomics: perspective of the Industry Pharmacogenomics Working Group (I-PWG). Human Genetics. 141(6). 1165–1173. 20 indexed citations

Holdsworth, Gill, James R Staley, Ian D. van Koeverden, et al.. (2020). Sclerostin Downregulation Globally by Naturally Occurring Genetic Variants, or Locally in Atherosclerotic Plaques, Does Not Associate With Cardiovascular Events in Humans. Journal of Bone and Mineral Research. 36(7). 1326–1339. 17 indexed citations

Petrovski, Slavé, Roberta Parrott, Joseph L. Roberts, et al.. (2016). Dominant Splice Site Mutations in PIK3R1 Cause Hyper IgM Syndrome, Lymphadenopathy and Short Stature. Journal of Clinical Immunology. 36(5). 462–471. 47 indexed citations

Williams, Victoria, Tao Yang, Christiana D. Ingram, et al.. (2015). Multiplex ligation-dependent probe amplification copy number variant analysis in patients with acquired long QT syndrome. EP Europace. 17(4). 635–641. 7 indexed citations

Wallentin, Lars, Stefan James, Robert F. Storey, et al.. (2010). Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial. The Lancet. 376(9749). 1320–1328. 582 indexed citations breakdown →

Storey, Robert F., Rachael Lawrance, Steen Husted, et al.. (2009). Ticagrelor yields consistent dose-dependent inhibition of ADP-induced platelet aggregation in patients with atherosclerotic disease regardless of genotypic variations inP2RY12, P2RY1,andITGB3. Platelets. 20(5). 341–348. 49 indexed citations

Granger, Christopher B., Peter Sinnaeve, Olof Bengtsson, et al.. (2008). Abstract 844: No Clear Association Between Candidate Gene Variants and Outcomes in 3239 Patients with Chronic Heart Failure: Results from the CHARM Program. Circulation. 118(18). 1 indexed citations

10.

Piotrovsky, Vladimir, Achiel Van Peer, Nancy Van Osselaer, Martin Armstrong, & Jeroen Aerssens. (2003). Galantamine Population Pharmacokinetics in Patients with Alzheimer's Disease: Modeling and Simulations. The Journal of Clinical Pharmacology. 43(5). 514–523. 27 indexed citations

11.

Leathart, Julian, Elaine Mutch, Stuart Dunn, et al.. (2002). CYP2C8 polymorphisms in Caucasians and their relationship with paclitaxel 6α-hydroxylase activity in human liver microsomes. Biochemical Pharmacology. 64(11). 1579–1589. 197 indexed citations

12.

Aerssens, Jeroen, Martin Armstrong, Ron Gilissen, & Nadine Cohen. (2001). The Human Genome: An Introduction. The Oncologist. 6(1). 100–109. 4 indexed citations

13.

Paulussen, Aimée, Karel Lavrijsen, Hilde Bohets, et al.. (2000). Two linked mutations in transcriptional regulatory elements of the CYP3A5 gene constitute the major genetic determinant of polymorphic activity in humans.. Pharmacogenetics. 10(5). 415–424. 74 indexed citations

14.

Pangalos, Menelas N., Peter Verhasselt, Roger Marrannes, et al.. (2000). Analysis of the humanKCNH2(HERG) gene: Identification and characterization of a novel mutation Y667X associated with long QT syndrome and a non-pathological 9 bp insertion. Human Mutation. 15(5). 483–483. 21 indexed citations

15.

Armstrong, Martin, Ann K. Daly, Richard Blennerhassett, Nicol Ferrier, & Jeffrey R. Idle. (1997). Antipsychotic drug-induced movement disorders in schizophrenics in relation to CYP2D6 genotype. The British Journal of Psychiatry. 170(1). 23–26. 67 indexed citations

16.

Armstrong, Martin, et al.. (1994). The cytochrome P450 CYP2D6 allelic variant CYP 2D6J and related polymorphisms in a European population. Pharmacogenetics. 4(2). 73–81. 49 indexed citations

17.

Cholerton, S., et al.. (1994). Debrisoquine 4-hydroxylation (CYP2D6) polymorphism in Jordanians. Pharmacogenetics. 4(3). 159–161. 10 indexed citations

18.

Armstrong, Martin, Jeffrey R. Idle, & Ann K. Daly. (1993). A polymorphic CfoI site in exon 6 of the human cytochrome P450 CYP2D6 gene detected by the polymerase chain reaction. Human Genetics. 91(6). 616–7. 19 indexed citations

19.

Idle, Jeffrey R., Martin Armstrong, Alan V. Boddy, et al.. (1992). The pharmacogenetics of chemical carcinogenesis. Pharmacogenetics. 2(6). 246–258. 53 indexed citations

20.

Daly, Ann K., et al.. (1991). Genetic and metabolic criteria for the assignment of debrisoquine 4-hydroxylation (cytochrome P4502D6) phenotypes. Pharmacogenetics. 1(1). 33–41. 78 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact